Failed 2026

    IO Biotech's Cylembio Narrowly Fails Phase 3, FDA Rejects BLA Path

    A single pivotal trial narrowly missing statistical significance can be as fatal to a biotech's near-term viability as an outright failure, especially when regulators require an entirely new registrational study.

    TL;DR — Failure Post-Mortem

    IO Biotech was a Biotechnology startup founded in 2014 in USA. It raised $170M (capital raised, not a verified loss) before shutting down in 2026, 12 years after founding. IdeaProof's Failure Score is 6/100, driven by filed for chapter 7 bankruptcy. The shutdown affected employees, investors, and the broader Biotechnology ecosystem. This case study breaks down the timeline, root causes, competitors that won, and replicable lessons for founders validating similar ideas today.

    Why did IO Biotech fail?

    IO Biotech failed in 2026 after 12 years of operation. $170M in raised capital. The root cause was filed for chapter 7 bankruptcy. Key lesson: A single pivotal trial narrowly missing statistical significance can be as fatal to a biotech's near-term viability as an outright failure, especially when regulators require an entirely new registrational study.

    Verifiable facts
    Sourced
    Founded → Closed

    2014 → 2026

    Funding Raised

    $170M

    Industry

    Biotechnology

    Country

    USA

    IdeaProof AI Failure Score

    6/100
    Market Fit Risk
    Burn Rate Risk
    Founder Risk

    What Happened: The Timeline

    •

    2025-08

    Phase 3 IOB-013 trial narrowly misses PFS significance

    •

    2025-09

    FDA recommends against BLA; company restructures

    Root Causes

    Phase 3 trial (IOB-013) narrowly missed statistical significance on progression-free survival
    FDA rejected pre-BLA pathway, recommending a new registrational study instead
    High cash burn on a single-asset late-stage program without a backup approval route
    Competitive first-line melanoma market dominated by established Keytruda-based regimens

    IO Biotech, a New York-based clinical-stage biotech, developed Cylembio, a therapeutic cancer vaccine to combine with Merck's Keytruda as first-line treatment for advanced melanoma. The pivotal Phase 3 trial IOB-013 evaluated Cylembio+Keytruda vs Keytruda alone. In August 2025, IO Biotech announced the trial showed clinically meaningful improvement in progression-free survival but 'narrowly missed' statistical significance. Despite this, IO Biotech initially pursued FDA approval. In September 2025, following a pre-BLA meeting, the FDA recommended against a BLA submission, urging IO Biotech to design a new registrational study. IO Biotech announced restructuring and workforce reduction.

    Causal Chain

    Derived · heuristic

    Interpretive pattern, not company-specific evidence: this chain is derived from the recorded failure reason and may apply to many companies with the same reason.Timeline dates, funding numbers and filings are facts (see methodology); root / proximate / terminal attribution is judgement based on public evidence.

    Root cause

    Phase 3 trial (IOB-013) narrowly missed statistical significance on progression-free survival

    Contributing factors
    • FDA rejected pre-BLA pathway, recommending a new registrational study instead
    • High cash burn on a single-asset late-stage program without a backup approval route
    • Competitive first-line melanoma market dominated by established Keytruda-based regimens
    Terminal event

    2026: shutdown (see sources for the documented terminal circumstances).

    Base rates

    External sources

    A single failure is an anecdote. These base rates give you the denominator — how common this outcome is across all startups matching IO Biotech's profile. Sources are third-party; we do not restate them as our own claims.

    ~35%
    all

    of new US employer businesses survive past their 10th year (Bureau of Labor Statistics BED series).

    US Bureau of Labor Statistics — BED (2024)

    Key Lessons Learned

    1. Phase 3 trial (IOB-013) narrowly missed statistical significance on progression-free survival

    Phase 3 trial (IOB-013) narrowly missed statistical significance on progression-free survival — a recurring pattern across biotechnology failures. Validate this risk before you scale.

    2. FDA rejected pre-BLA pathway, recommending a new registrational study instead

    FDA rejected pre-BLA pathway, recommending a new registrational study instead — a recurring pattern across biotechnology failures. Validate this risk before you scale.

    3. High cash burn on a single-asset late-stage program without a backup approval route

    High cash burn on a single-asset late-stage program without a backup approval route — a recurring pattern across biotechnology failures. Validate this risk before you scale.

    Frequently Asked Questions

    Sources & Confidence

    Every data point is tagged with its source type and our confidence in it. How we grade sources.

    Additional references
    Cancer vaccine's 'narrow' fail won't stop IO heading to FDA

    Could This Failure Have Been Prevented?

    IdeaProof's AI validates market demand, competitive positioning, and business model viability in minutes — catching the exact issues that sank IO Biotech.

    Related Failures

    Sichuan Kelun-Biotech

    $400M · 2024

    Capital inefficiency, weak pipeline, market saturation

    Base Therapeutics

    $34.5M · 2025

    Product/tech failure, capital inefficiency

    Lipella Pharmaceuticals

    Under $20m · 2026

    Bankruptcy, inability to develop drug

    Lipocine Inc.

    $150m+ · 2026

    Phase 3 trial failed primary endpoint

    Spotted a factual error?

    Approved corrections are published in the public changelog with attribution.

    After IO Biotech: hubs, comparisons and deep dives

    Compare the validation, funding and go-to-market choices that separate survivors from failures like IO Biotech.